Multiscale Selectivity and in vivo Biodistribution of NRP-1Targeted Theranostic AGuIX Nanoparticles for PDT of Glioblastoma.
Fiche publication
Date publication
janvier 2020
Journal
International journal of nanomedicine
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BARBERI-HEYOB Muriel, Dr CHOULIER Laurence, Dr FROCHOT Céline, Dr THOMAS Noémie, Dr DAOUK Joël
Tous les auteurs :
Gries M, Thomas N, Daouk J, Rocchi P, Choulier L, Jubréaux J, Pierson J, Reinhard A, Jouan-Hureaux V, Chateau A, Acherar S, Frochot C, Lux F, Tillement O, Barberi-Heyob M
Lien Pubmed
Résumé
Local recurrences of glioblastoma (GBM) after heavy standard treatments remain frequent and lead to a poor prognostic. Major challenges are the infiltrative part of the tumor tissue which is the ultimate cause of recurrence. The therapeutic arsenal faces the difficulty of eradicating this infiltrating part of the tumor tissue while increasing the targeting of tumor and endogenous stromal cells such as angiogenic endothelial cells. In this aim, neuropilin-1 (NRP-1), a transmembrane receptor mainly overexpressed by endothelial cells of the tumor vascular system and associated with malignancy, proliferation and migration of GBM, highlighted to be a relevant molecular target to promote the anti-vascular effect of photodynamic therapy (VTP).
Mots clés
AGuIX nanoparticle, NRP-1, brain tumors, glioblastoma, peptide, radiation therapies, vascular photodynamic therapy
Référence
Int J Nanomedicine. 2020 ;15:8739-8758